TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

THE GOOD
Business Development

Novo Nordisk buys 2seventy bio Hemophilia A asset for $40M
In vivo gene editing therapy, hemophilia A - Read more

Nxera Pharma hits R&D milestone, triggers $10M payment from AbbVie
Drug discovery, G protein-coupled receptor, neurological disease - Read more

THE GOOD
Clinical Trials

Silence Therapeutics reports encouraging early Ph1 blood disorder data
siRNA, polycythemia vera - Read more

CalciMedica rushes into Ph3 after positive Ph2b results in acute pancreatitis
Small molecule, acute pancreatitis, systemic inflammatory response syndrome - Read more

X4 Pharmaceuticals’ positive interim Ph2 data
Small molecule, chronic neutropenia - Read more

THE GOOD
Company Launches

WayPoint Bio launches to “test hundreds [of cell therapies] at once”
Cell therapy, CAR-T, spatial biology - Read more [Paywall]

THE GOOD
Fundraises

Holoclara $16M Series A
Worm-derived therapies, autoimmune, allergies - Read more

Ovax $10M raise
Vaccine, opioid overdose, fentanyl - Read more

Carelane €800K ($855K) pre-seed raise
Clinical trial operations, digitization - Read more

Recursion Pharmaceuticals $200M public offering
Drug discovery, machine learning - Read more

NeOnc Technologies $18.5M Financing
Small molecule, blood-brain barrier, cancer - Read more

Bold Capital Partners aiming to raise new $200M growth fund
Biotech, diagnostics, longevity - Read more [Paywall]

THE GOOD
Investments

Vigil Therapeutics receive $40M strategic investment from Sanofi
Small molecule, monoclonal antibody, microglial dysfunction, leukoencephalopathy with axonal spheroids and pigmented glia - Read more

THE GOOD
Mergers & Acquisitions

AbbVie brings the heat, buys Celsius Therapeutics for $250M cash
anti-TREM1 antibody, inflammatory bowel disease - Read more

Laboratorios Farmacéuticos Rovi’s CDMO division receives buy-out offers, upwards of €3.5B ($3.74B)
CDMO, manufacturing - Read more

CASI courts buy-out offer for their China business operations from their own chairman & CEO
Monoclonal antibody, antibody-mediated rejection - Read more

Biogen’s hungry for more M&A deals - Read more [Paywall]

THE GOOD
Partnerships

Kite Pharma signs on to asses Cellares’ cell therapy manufacturing platform
Cell therapy manufacturing platform, automated - Read more 

THE GOOD
Politics & Policy

Medicare inches closer to covering weight loss drugs
Obesity, medicare, drug costs - Read more

THE GOOD
Product Launches

Eisai, Biogen’s Leqembi launches in China
Monoclonal antibody, Alzheimer’s - Read more

THE GOOD
Research

What can’t it do? Study looks into GLP-1 meds treating PCOS
GLP-1, semaglutide, polycystic ovary syndrome - Read more

Mice studies show promise for potential molecular editing tool targeting prion diseases
Molecular editing, prion disease, neurodegenerative disorder - Read more

THE GOOD
Strategic Plans

Maze Therapeutics spins out ALS antisense asset
Antisense oligonucleotide, amyotrophic lateral sclerosis - Read more [Paywall]

GSK aims for 100% renewable electricity at all Singapore sites by end of 2025 - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Merck, Daiichi Sankyo’s lung cancer mAb hit with FDA CRL; third party manufacturing issues
Antibody-drug conjugate, lung cancer - Read more

THE BAD
Business Development

Coherus Biosciences offloads Humira biosimilar for a less-than-stellar $40M
Monoclonal antibody, autoimmune disorders - Read more [Paywall]

THE BAD
Layoffs

EuroAPI reveals restructuring strategy and future layoffs
Small molecule, active pharmaceutical ingredient manufacturing - Read more

Bayer planning more managerial cuts as part of reorganization - Read more [Paywall]

Sumitomo Pharma considers layoffs in light of decreasing revenue - Read more

THE BAD
Mergers & Acquisitions

Future Pak withdraws Vanda Pharmaceuticals acquisition proposal
Small molecule, psychiatric, antipsychotic - Read more

THE UGLY
Lawsuits

SCOTUS rejects Purdue Pharma, Sackler Family opioid settlement
Opioid epidemic, bankruptcy - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 450+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.